Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

Journal of Immunotherapy

Volumn 31, Issue 6, 2008, Pages 569-576

  Acquavella, Nicolas ^a   Kluger, Harriet ^b   Rhee, John ^b,c   Farber, Leonard ^b,c   Tara, Harold ^b,c   Ariyan, Stephan ^b   Narayan, Deepak ^b   Kelly, William ^d   Sznol, Mario ^b,d  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b Melanoma Program   (United States)

^c Medical Oncology and Hematology ^*

^d YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

High dose; Interleukin 2; Metastatic melanoma; Metastatic renal cancer; Toxicity

Indexed keywords

AMINOTRANSFERASE; ANESTHETIC AGENT; ATROPINE PLUS DIPHENOXYLATE; BICARBONATE; CEFAZOLIN; CLINDAMYCIN; CODEINE; CORTICOSTEROID DERIVATIVE; CREATININE; DERMATOLOGICAL AGENT; DIPHENHYDRAMINE; FAMOTIDINE; FLUORODEOXYGLUCOSE F 18; HYDROXYZINE; HYPERTENSIVE FACTOR; INDOMETACIN; LIDOBENALOX; LOPERAMIDE; LORAZEPAM; LUBRIDERM; ONDANSETRON; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE MALEATE; PSEUDOEPHEDRINE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; UNCLASSIFIED DRUG; ZOLPIDEM; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; LEUKOCYTE ANTIGEN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; BICARBONATE BLOOD LEVEL; BOLUS INJECTION; BONE LESION; BRAIN METASTASIS; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; CATHETER THROMBOSIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONFUSION; CONVALESCENCE; CREATININE URINE LEVEL; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE BALANCE; FATIGUE; FEMALE; FEVER; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INTENSIVE CARE; INTRAVENOUS ADMINISTRATION; INTUBATION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER INJURY; LIVER METASTASIS; LUNG LESION; MALE; MEDICAL RECORD REVIEW; MELANOMA; MENTAL HEALTH; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOCARDITIS; NAUSEA; NAUSEA AND VOMITING; OXYGEN THERAPY; PATIENT MONITORING; PATIENT TRANSPORT; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIORITY JOURNAL; RECURRENT CANCER; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SKIN DEFECT; SPINAL PAIN; SPLEEN; SUBCUTANEOUS TISSUE; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT GAIN; DRUG ADMINISTRATION; IMMUNOLOGY; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED;

EID: 48549087937     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318177a4ba     Document Type: Article

References (19)

1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
2. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
3. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
4. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
5. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: longterm survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14.
6. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57.
7. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797-805.
8. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993;11:1969-1977.
9. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother (1997). 2001;24:287-293.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
11. Dutcher J, Atkins MB, Margolin K, et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol. 2001;18:209-219.
12. Lotze MT, Frana LW, Sharrow SO, et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985;134:157-166.
13. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169-1188.
14. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985;135:2865-2875.
15. Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin- 2. Cancer Res. 1986;46:2784-2792.
16. Abrams JS, Rayner AA, Wiernik PH, et al. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst. 1990;82: 1202-1206.
17. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13: 6681-6688.
18. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968-8977.
19. Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother (1997). 2007;30:130.